Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications. Especially an extensive spectrum of dermatologic toxicities has been associated with cancer treatments. The number and type of cutaneous toxicities have evolved over the past 50 years, paralleling the development of new radiotherapy (RT) techniques. Acute radiodermatitis (ARD) is a distressing and painful skin reaction that occurs in 95% of the patients undergoing RT. Important organizations in the field of oncology and supportive care, such as the MASCC, the ASCO, and the ESMO, have developed guidelines for the management of cancer therapy- related cutaneous toxicities based on available scientific evidence. Still, for some interventions, the evidence of recommendation is moderate to insufficient. Therefore, it is essential to elucidate other new potential management strategies for dermatological complications of cancer treatment. Based on the previously mentioned supportive care guidelines for the RTskin project, a novel emollient to tackle ARD has been developed. The RTskin project general aim is to evaluate the efficacy of a novel skincare product to manage ARD in breast cancer patients.
Primary objective Evaluate the efficacy of a novel emollient for the management of ARD in comparison with the current standard of care in breast cancer patients Secondary Objective 1 Compare the ARD-related symptoms of in breast cancer patients treated with the novel emollient and the standard institutional skin care. Secondary Objective 2 Compare the dermatologic quality of life of in breast cancer patients treated with the novel emollient and the standard institutional skin care. Secondary Objective 3 Correlate the severity of ARD with the applied RT parameters and personal - medical characteristics
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
100
The emollient has a calming effect, and hydrating and anti-oxidative properties. An absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
The control patients will receive the institutional standard skin care, which includes the application of Flamigel® (Flen Pharma, Kontich, BELGIUM). In addition, Mepilex® (Mölnlycke Health Care, Berchem, Belgium), an absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
Jessa Ziekenhuis VZW
Hasselt, Limburg, Belgium
Skin reaction evaluation
The patients skin reactions will be evaluated by the modified version of the RTOG criteria
Time frame: Baseline
Skin reaction evaluation
The patients skin reactions will be evaluated by the modified version of the RTOG criteria
Time frame: At fraction 15-16 of radiotherapy (week 3 )
Skin reaction evaluation
The patients skin reactions will be evaluated by the modified version of the RTOG criteria
Time frame: At fraction 20-21 of radiotherapy (week 4) in case of a tumor boost
Patient subjective evaluation of skin reactions
The patients will be asked to complete a questionnaire to evaluate the intensity and frequency of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale
Time frame: Baseline
Patient subjective evaluation of skin reactions
The patients will be asked to complete a questionnaire to evaluate the intensity and frequency of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale
Time frame: Week 1 of radiotherapy
Patient subjective evaluation of skin reactions
The patients will be asked to complete a questionnaire to evaluate the intensity and frequency of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale
Time frame: Week 2 of radiotherapy
Patient subjective evaluation of skin reactions
The patients will be asked to complete a questionnaire to evaluate the intensity and frequency of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale
Time frame: At fraction 15/16 of radiotherapy (week 3)
Patient subjective evaluation of skin reactions
The patients will be asked to complete a questionnaire to evaluate the intensity and frequency of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale
Time frame: At fraction 20/21 of radiotherapy (week 4) in case of a tumor boost
Quality of life assessment
The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items).
Time frame: Baseline
Quality of life assessment
The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items).
Time frame: At fraction 15/16 of radiotherapy (week 3)
Quality of life assessment
The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items).
Time frame: At fraction 20/21 of radiotherapy (week 4) in case of a tumor boost
Patients' satisfaction with the therapeutic intervention
The patients will be asked to evaluate the general pleasantness and soothing effect of the skin care products. Furthermore, they will be asked to score their global satisfaction with the skin care products. All these items will be evaluated by using a numerical rating scale (NRS).
Time frame: At fraction 15/16 of radiotherapy (week 3)
Patients' satisfaction with the therapeutic intervention
The patients will be asked to evaluate the general pleasantness and soothing effect of the skin care products. Furthermore, they will be asked to score their global satisfaction with the skin care products. All these items will be evaluated by using a numerical rating scale (NRS).
Time frame: At fraction 20/21 of radiotherapy (week 4) in case of a tumor boost
Pruritus evaluation
The patients' degree of pruritus will be evaluated by the NCI-CTCAE V5 criteria
Time frame: Baseline
Pruritus evaluation
The patients' degree of pruritus will be evaluated by the NCI-CTCAE V5 criteria
Time frame: At fraction 15/16 of radiotherapy (week 3)
Pruritus evaluation
The patients' degree of pruritus will be evaluated by the NCI-CTCAE V5 criteria
Time frame: At fraction 20/21 of radiotherapy (week 4) in case of a tumor boost
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.